Abstract:This study describes the localization and computational prediction of a binding site for the A 3 adenosine receptor (A 3 AR) positive allosteric modulator 2-cyclohexyl-1 H -imidazo[4,5-c]quinolin-4-(3,4-dichlorophenyl)amine (LUF6000). The work reveals an extrahelical lipid-facing binding pocket disparate from the orthosteric binding site that encompasses transmembrane domain (TMD) 1, TMD7, and Helix (H) 8, which was predicted by molecular modeling and validated by mutagenesis. According to the model, the nearly planar 1 H -imidazo[4,5-c]quinolinamine ring system lies parallel to the transmembrane segments, inserted into an aromatic cage formed by - stacking interactions with the side chains of Y284 7.55 in TMD7 and Y293 8.54 in H8 and by -NH bonding between Y284 7.55 and the exocyclic amine. The 2-cyclohexyl group is positioned "upward" within a small hydrophobic subpocket created by residues in TMDs 1 and 7, while the 3,4-dichlorophenyl group extends toward the lipid interface. An H-bond between the N - 1 amine of the heterocycle and the carbonyl of G29 1.49 further stabilizes the interaction. Molecular dynamics simulations predicted two metastable intermediates, one resembling a pose determined by molecular docking and a second involving transient interactions with Y293 8.54 ; in simulations, each of these intermediates converges into the final bound state. Structure-activity-relationships for replacement of either of the identified exocyclic or endocyclic amines with heteroatoms lacking H-bond donating ability were consistent with the hypothetical pose. Thus, we characterized an allosteric pocket for 1 H -imidazo[4,5-c]quinolin-4-amines that is consistent with data generated by orthogonal methods, which will aid in the rational design of improved A 3 AR positive allosteric modulators. SIGNIFICANCE STATEMENT Orthosteric A 3 AR agonists have advanced in clinical trials for inflammatory conditions, liver diseases, and cancer. Thus, the clinical appeal of selective receptor activation could extend to allosteric enhancers, which would induce site- and time-specific activation in the affected tissue. By identifying the allosteric site for known positive allosteric modulators, structure-based drug discovery modalities can be enabled to enhance the pharmacological properties of the 1 H -imidazo[4,5-c]quinolin-4-amine class of A 3 AR positive allosteric modulators.

QSAR Analysis of Human Adenosine A3 Receptor Antagonists

Comparison of the Selectivity of Human Adenosine Receptor Antagonists Based on Structure and Pharmacophore Features

Medicinal chemistry of adenosine A3 receptor ligands

Hit-to-Lead Optimization of Heterocyclic Carbonyloxycarboximidamides as Selective Antagonists at Human Adenosine A3 Receptor

Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A 3 Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary

Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261

The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: application to a lead optimization of a human A3 adenosine receptor antagonist

Species differences and mechanism of action of A3 adenosine receptor allosteric modulators

Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Machine Learning for Discovery of New ADORA Modulators

Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors

2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives

Progress in the pursuit of therapeutic adenosine receptor antagonists

Structure-Activity Studies of 1 H -Imidazo[4,5- c ]quinolin-4-amine Derivatives as A 3 Adenosine Receptor Positive Allosteric Modulators

Novel Scaffold Agonists of the α2A Adrenergic Receptor Identified via Ensemble-Based Strategy

Extrahelical Binding Site for a 1H-Imidazoquinolin-4-amine A3 Adenosine Receptor Positive Allosteric Modulator on Helix 8 and Distal Portions of Transmembrane Domains 1 and 7

Cryo-EM structures of adenosine receptor A3AR bound to selective agonists

The Discovery of Novel α2a Adrenergic Receptor Agonists Only Coupling to Gαi/O Proteins by Virtual Screening

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

Design, Synthesis and Biological Evaluation of 1,3,5-Triazine Derivatives Targeting hA1 and hA3 Adenosine Receptor